Literature DB >> 10226059

Mucous-cell metaplasia and inflammatory-cell recruitment are dissociated in allergic mice after antibody- and drug-dependent cell depletion in a murine model of asthma.

S Haile1, J Lefort, D Joseph, P Gounon, M Huerre, B B Vargaftig.   

Abstract

Inflammatory-cell infiltration and epithelial modifications are prominent lesions of the bronchial mucosa in asthma and in experimental allergic bronchopulmonary inflammation. However, the recruitment of inflammatory cells and their relationship to the epithelial modifications and to functional alterations such as bronchopulmonary hyperreactivity (BHR) are less known. We studied the mechanisms of antigen-dependent inflammatory-cell recruitment to the lungs and the associated lesions and their relationship using drug- and antibody-dependent cell-depletion procedures. A single intranasal ovalbumin challenge in BP2 mice was found to induce hyperreactivity within 1 h after challenge, followed by the massive infiltration of immunoglobulin (Ig)E-bearing polymorphonuclear leukocytes (PMN), and eosinophils, and by a mucous-cell metaplasia of the bronchiolar epithelium. Similarly challenged BALB/c mice did not exhibit BHR, despite a moderate recruitment of inflammatory cells and mucous-cell metaplasia. Inflammatory-cell recruitment, mucous-cell metaplasia, and BHR were prevented by prior antibody-dependent depletion of CD3(+) lymphocytes and partially inhibited by the depletion of CD4(+) lymphocytes. Treatment with the granulocytopenic drug vinblastine before challenge completely abolished the recruitment of granulocytes without affecting the antigen-induced mucous-cell metaplasia. In this study two new key elements of the murine model of allergic pulmonary inflammation are described: the recruitment of IgE-bearing PMN between 3 and 72 h after challenge, and the dissociation between granulocytes and mucous-cell metaplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226059     DOI: 10.1165/ajrcmb.20.5.3446

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  7 in total

1.  Regulatory T cells and regulation of allergic airway disease.

Authors:  Helen Martin; Christian Taube
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

2.  Murine myeloid progenitor responses to GM-CSF and eosinophil precursor responses to IL-5 represent distinct targets for downmodulation by prostaglandin E(2).

Authors:  M I Gaspar Elsas; D Joseph; L Lintomen; E S Maximiano; M Bodstein; P Xavier Elsas; B B Vargaftig
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

3.  Airway hyperresponsiveness in the absence of CD4+ T cells after primary but not secondary challenge.

Authors:  Anthony Joetham; Katsuyuki Takeda; Christian Taube; Nobuaki Miyahara; Arihiko Kanehiro; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2005-04-21       Impact factor: 6.914

4.  Pathogenesis of mucous cell metaplasia in a murine asthma model.

Authors:  J Rachel Reader; Jeffrey S Tepper; Edward S Schelegle; Melinda C Aldrich; Lei F Putney; Juergen W Pfeiffer; Dallas M Hyde
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

5.  Bronchial lesions of mouse model of asthma are preceded by immune complex vasculitis and induced bronchial associated lymphoid tissue (iBALT).

Authors:  Ian C Guest; Stewart Sell
Journal:  Lab Invest       Date:  2015-06-01       Impact factor: 5.662

Review 6.  Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity.

Authors:  Francis Davoine; Paige Lacy
Journal:  Front Immunol       Date:  2014-11-10       Impact factor: 7.561

7.  Acute oral toxicity of Insampaedok-san, a traditional herbal formula, in rats and its protective effects against ovalbumin-induced asthma via anti-inflammatory and antioxidant properties.

Authors:  Yeji Kim; Mee-Young Lee; Ohn-Soon Kim; Woo-Young Jeon; Hyeun-Kyoo Shin
Journal:  BMC Complement Altern Med       Date:  2014-09-29       Impact factor: 3.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.